Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 26, 2025
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 26, 2025
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
March 26, 2025
PARAMUS, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the Company …
Pentec Expands into Digital Therapeutic Services Through Partnership with Luminopia
GlobeNewswire
·
March 26, 2025
BOOTHWYN, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Pentec Health, Inc., a leading complex care provider, delivers specialty pharmacy and infusion services nationwide, serving patients with chronic and rare diseases in underserved markets. The company is now …
Sofwave to Participate in Upcoming Conferences
GlobeNewswire
·
March 26, 2025
SAN CLEMENTE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf …
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 26, 2025
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual …
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
GlobeNewswire
·
March 26, 2025
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
GlobeNewswire
·
March 26, 2025
SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, and City of Hope, one of …
Dewpoint Therapeutics announces upcoming presentations at AACR 2025
GlobeNewswire
·
March 26, 2025
Dewpoint will present two posters at AACR Condensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancer C-mods modulate the oncogenic function of historically undruggable targets MYC and beta catenin BOSTON, March 26, …
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
GlobeNewswire
·
March 26, 2025
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the …
E-Star BioTech Announces Presentation During 2025 Annual Meeting of the American College of Cardiology
GlobeNewswire
·
March 26, 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced its presentation of clinical trial …
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
GlobeNewswire
·
March 26, 2025
CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate therapeutics, announced that a series of antiviral …
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
GlobeNewswire
·
March 26, 2025
Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious …
Catheter Precision to Participate in and Share Data at Upcoming Industry Conferences
GlobeNewswire
·
March 26, 2025
FORT MILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their …
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
GlobeNewswire
·
March 26, 2025
NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s …
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
GlobeNewswire
·
March 26, 2025
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung …
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
GlobeNewswire
·
March 26, 2025
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single …
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
GlobeNewswire
·
March 26, 2025
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de …
Thérapeutique Knight annonce le lancement de Minjuvi® (tafasitamab) au Mexique
GlobeNewswire
·
March 26, 2025
MONTRÉAL, 26 mars 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight Inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui le lancement de Minjuvi® (tafasitamab) par sa filiale mexicaine, Grupo …
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
GlobeNewswire
·
March 26, 2025
CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug …
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
GlobeNewswire
·
March 26, 2025
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik …